header logo image


Page 970«..1020..969970971972..980990..»

Nanomedicine: Nanotechnology, Biology and Medicine – Official Site

July 5th, 2017 8:44 pm

The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine.

Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results...

The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine.

Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases. In addition to bimonthly issues, the journal website (http://www.nanomedjournal.com) also presents important nanomedicine-related information, such as future meetings, meeting summaries, funding opportunities, societal subjects, public health, and ethical issues of nanomedicine.

The potential scope of nanomedicine is broad, and we expect it to eventually involve all aspects of medicine. Sub-categories include synthesis, bioavailability, and biodistribution of nanomedicines; delivery, pharmacodynamics, and pharmacokinetics of nanomedicines; imaging; diagnostics; improved therapeutics; innovative biomaterials; interactions of nanomaterials with cells, tissues, and living organisms; regenerative medicine; public health; toxicology; point of care monitoring; nutrition; nanomedical devices; prosthetics; biomimetics; and bioinformatics.

Article formats include Communications, Original Articles, Reviews, Perspectives, Technical and Commercialization Notes, and Letters to the Editor. We invite authors to submit original manuscripts in these categories. The journal website (http://www.nanomedjournal.com) also presents important nanomedicine-related information, such as future meetings, meeting summaries, funding opportunities, societal subjects, public health, and ethical issues of nanomedicine.

Follow this link:
Nanomedicine: Nanotechnology, Biology and Medicine - Official Site

Read More...

Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 – PR Newswire (press release)

July 5th, 2017 8:44 pm

LONDON, July 5, 2017 /PRNewswire/ -- "Global Nano Chemotherapy Market & Clinical Trials Outlook 2022" report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.

Download the full report: https://www.reportbuyer.com/product/4884894/

Nano chemotherapy is emerging as an important anti-cancer modality by supplementing the traditional chemotherapy. The main aim of nano chemotherapeutics is to improve the therapeutic efficacy of currently available chemotherapeutic agents by combining it with a nano scale delivery component. The majority of the cancer nanodrugs in the market are liposomes and polymer based nanoformulations which lower the toxicity and enhance the delivery of chemotherapeutics through the passive targeting. It is based on enhanced penetration and retention effect to reduce the lymphatic drainage in tumor tissue.

Conventional chemotherapeutic agents are distributed non-specifically in body where they affect both cancerous and normal cells and thereby it limit the dose availability with in the tumor and also results in suboptimal treatment due to excessive toxicities. To overcome the limitations of chemotherapy treatment, many more therapies has also been emerged.

The use of nanoparticles by both passive and active targeting strategies can enhance the intracellular concentration of drugs in cancer cells while avoiding the toxicity in normal cells. When the nanoparticles bind to a specific receptors and then enter the cell, usually enveloped by endosomes through receptor mediated endocytosis and thereby bypassing the recognition of P glycoprotein.

Nanomedicine has already met with success in oncology domain with various product commercially available in the market. By releasing the efficacy of nanomedicine in oncology, it increases the interest of the market players to commercialize the products in the field of nanotherapeutics and helps to increase the global market. The future of nanotherapeutics is bright and especially for the reversible cross linked nano carriers which are decorated with the cancer targeting ligands and it promote the endocytic uptake in tumor cells. The approach has the potential to overcome the drug resistance which is often with conventional chemotherapies.

For the next generation cancer nanotherapeutics, the complexity is higher which are under clinical development in terms of hybrid structures, surface physiochemical characteristics and mechanisms of delivery and action. There have been rapid advances in the nano therapeutic field in the past decade. Many of the nano carriers have been developed from which some have the great therapeutic potential. However, there remain many challenges in translating the nanoparticle drugs into the clinics. Download the full report: https://www.reportbuyer.com/product/4884894/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-nano-chemotherapy-market--clinical-trials-outlook-2022-300483678.html

Here is the original post:
Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 - PR Newswire (press release)

Read More...

Metallic nanomolecules could help treat fatal lung disease in the future, notes research – EPM Magazine

July 5th, 2017 8:44 pm

New research from Imperial College London, that has recently been published online, examined a novel type of nanoparticle called metal organic frameworks (MOF) as drug carriers for the treatment of pulmonary arterial hypertension (PAH).

Published in Pulmonary Circulation, the research describes the first steps in the development of nanoparticles that can deliver drugs directly to the lungs. The MOFs, created in the laboratory by the researchers, are composed of iron and can expand to create pores within which drugs used to treat PAH can be stored and released where needed.

The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects, explained Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial in a news release. For patients with PAH, it could mean we are able to turn it from a fatal condition, to a chronic manageable one.

When testing the MOFs, the team from Imperial found that the structures reduced inflammation and were not toxic to human lung cells and blood vessels in laboratory conditions. Further testing in rats, showed the MOFs were safe in the animal model over a two-week period with few side-effects a slight build-up of iron was seen in the liver.

One of the biggest limitations in nanomedicine is toxicity, some of the best nanomedicine structures do not make it past the initial stages of development as they kill cells, continued Mitchell. We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells.

The aim is to develop the metallic structures as a drug delivery method where the framework can hold onto the drug and release it under specific conditions, such as a change in pH, temperature or using magnets external to the body to draw the MOFs to the target area. Next steps for this research is to discover the ideal way to get the tiny structures loaded with drugs and delivered to the lungs effectively.

In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung, Mitchell concluded. This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery.

Read more from the original source:
Metallic nanomolecules could help treat fatal lung disease in the future, notes research - EPM Magazine

Read More...

Support Ella’s Endeavor with Autism – Areawide News

July 5th, 2017 8:44 pm

Ella Beggs

The autism spectrum is broad and affects 1 in 68 children in the United States alone. For one local child, Ella Beggs, her family is working to raise money to take Ella to Panama for treatment for her autism.

The fundraiser will take place at the Old Hardy Gym, July 8 starting at 5 p.m. and will include a live auction, concert and BBQ dinner. All proceeds will be used to help Ella and her family travel to Panama for treatment.

According to Scarlett Beggs, Ellas mom, the treatment uses stem cells in order to help alleviate the developmental delays created by autism.

Michael and I are always researching things to just help her be her best and we found stem cell research online from a place called the Stem Cell Institute of Panama, where they do stem cell treatment for autism, Beggs said. Its done in several different places; China, Mexico and India too but Panama is where we have seen the most testimonials from. We contacted them and researched as much as we could and found that with the stem cell treatment for autism, kids that were completely non-verbal before, had started talking in full sentences. Kids that were not potty trained before, were able to potty train and just an overall improvement from stem cells.

Beggs said initially she was hesitant to travel to a foreign country in order to have her daughter undergo treatment, however the further she researched, the more comfortable she became with the idea.

They are doing trial runs in the U.S., but it takes so long to get things approved through the FDA; who knows when theyll get it done here. In order to be eligible for the trials here [in the United States], you have to have your own [umbilical] cord blood bank and we dont have Ellas, so we have to rely on donated cord blood, Beggs said. Its a simple process. Its like a blood transfusion. Shell go for a week and theyll do it through an IV and the only side effects theyve seen are very mild. With such a low risk, we have to give it a try. It cant hurt her. Its shell either stay the same or show improvement.

So far, the family has been able to raise a little less than half of the $20,000 which they will need in order to make the weeklong trip.

They would like to invite the community to come out and support Ellas Endeavor with Autism.

View original post here:
Support Ella's Endeavor with Autism - Areawide News

Read More...

Wheelchair-bound Langley man raising funds for stem cell therapy in Central America – Surrey Now-Leader

July 5th, 2017 8:44 pm

Logan Van Dyk hopes stem cell operation in Central America will open doors for him ones that shut abruptly on Aug. 3, 2008.

It took seconds for the now 26-year-old Fort Langley residents life to change.

On that day nearly nine years ago, just after he graduated from R.E. Mountain Secondary, Van Dyk suffered a life-altering spinal cord injury in a mountain biking incident.

I was fooling around on a construction site with some friends and I accidentally fell off a dirt pile on my bike, recalled Van Dyk, who was born and raised in Langley. I fell 25 feet and landed on my face.

Van Dyk suffered a spinal cord injury that left him bound to a wheelchair, as a partial quadriplegic.

I got a C56 spinal cord injury, but its incomplete which means theres always a possibility for recovery, Van Dyk said.

Its that hope that has Van Dyk looking to travel to Panama for therapy.

He started doing some research on stem cells and found an institute in Panama City that offers treatments.

Van Dyk sent in an application and on March 8 received an email saying he will make an excellent candidate for stem cell therapy.

Of course there is no guarantee that I will gain anything back but at this point Im willing to try anything to improve the quality of my life, said Van Dyk, who hopes to get into broadcasting.

He has created a GoFundMe page to raise what he believes is the $45,000 necessary to pay for flights, treatments, accommodations, and a personal nurse in Panama City. Visit http://www.gofundme.com/anw8ce-stem-cell-research.

The therapy itself will cost roughly $37,400 US. As well, there are no nurses at the institute who would assist Van Dyk directly.

I receive care twice a day in order to get in and out of my wheelchair and in and out of bed, Van Dyke explained. So I need to get a bit of extra money so I can hire a nurse to come down with me. Im not sure how much that is going to cost.

A friend who works as a nurse guided Van Dyk towards the possibility of travelling to Panama.

She couldnt believe there was nothing that could be done given the circumstances of my injury, Van Dyke said, because Ive got feeling all the way down to my toes. She looked into it and she found this down in Panama City. We looked at it and found some testimonials from some people who have gone down. They say they have about a 75 per cent success rate.

Van Dyk said he always does his best to remain positive and happy in everything he does.

Even the most basic of things take all my effort to achieve, Van Dyk said on his GoFundMe page. There just had to be something out there that could make things easier.

However, time is running out.

Unfortunately, the cutoff is 10 years, Van Dyk said. They wont do this treatment on anybody whose injury is over 10 years old. Im at my deadline.

Positive attitude

After the accident, Van Dyk was told by doctors that it was very unlikely he would ever walk again and would need to be in a power wheelchair for the rest of his life.

Van Dyk said much to their surprise, he wasnt able to accept that and he worked as hard as possible to overcome the barriers the medical world presented him with, and within a few months started using a manual wheelchair every day.

Mobility however, did not return and life has been a constant struggle ever since.

Keeping Van Dyk moving forward has been a positive attitude, and he quickly adapted to his new life in a wheelchair. It was pretty easy to get over it. I never had trouble finding the positives in life. I kind of adapted. A lot of people would say that I am the most positive person that theyve ever met. I get compliments a lot on how well I actually dealt with the injury. It was difficult but it was easy at the same time.

Van Dyk is now turning to the public to help him regain some freedom.

I miss the active lifestyle I led prior to injury, and am getting really tired of sitting all day long with a limited amount of things I can do to entertain myself, Van Dyk said. Im as independent as a I can be and I still rely on a lot of help. If I can get anything back, even just a bit more upper body Im just looking for anything at this point.

Read more:
Wheelchair-bound Langley man raising funds for stem cell therapy in Central America - Surrey Now-Leader

Read More...

Report: Crandon girl, 6, died of complications from diabetes – WSAW

July 5th, 2017 8:43 pm

CRANDON, Wis. (WSAW) -- The Forest/Oneida County medical examiner has determined the death of a 6-year-old child that died March 7 was caused by complications from diabetes.

Larry Mathein wrote Amber Perry's death is a homicide due to diabetic ketoacidosis, as he stated Perry did not receive proper management for her condition.

According to the report, family was aware Perry had insulin dependent diabetes.

"The severity of the dehydration discovered at autopsy would indicate a long term, chronic, lack of proper management of this decedent's medical condition," Mathein wrote in the report.

"I do not believe "accident" is appropriate due to the obvious chronic presentation of the physical condition of Amber's body", it reads.

Doctor Larry Gordon, a pediatrician who treats almost 200 people with diabetes explains what signs Amber Perry's family should have seen as she had diabetic ketoacidosis. "It messes with your respiration, it messes with your ability to get good blood flow to your body, as you get dehydrated your body automatically reacts," Gordon said. "Your body will just start slowly shutting down, your circulation, to try and conserve that flow and it's really going to take a toll on your body."

Another common part of diabetic ketoacidosis is a build-up of carbon dioxide. Doctors look for heavy breathing, since that's usually a sign of the body trying to get rid of carbon dioxide. This is also when patients can slip into a coma.

Crandon police responded to the report of an unresponsive child around 8 a.m. on Tuesday, March 7 to the Grant Apartments located at 400 Grant St. in Crandon. Initially, investigators called Perry's death suspicious.

Gordon also says it's important to remember that every diabetes patient is different, which means we can't know exactly what Amber experienced before she died.

The report did not blame any one person for Perry's death, but stated several persons were responsible for her day-to-day care.

In a separate unrelated case, a Wausau couple was convicted of reckless homicide in separate trials after their daughter, 11-year-old Madeline Kara Neumann, died of untreated diabetes March 2008. Dale and Leilani Neumann's were each sentenced to 180 days in jail and 10 years of probation. Prosecutors said the Neumanns chose to pray for their daughter, instead of seeking medial treatment.

See original here:
Report: Crandon girl, 6, died of complications from diabetes - WSAW

Read More...

Researcher may have found a cure for diabetes – New York Post

July 5th, 2017 8:43 pm

Ending the worlds diabetes epidemic could be one step closer, with a promising new technique curing the condition in mice.

Scientists at the University of Texas announced the breakthrough, which uses a novel approach that may eliminate Type 1 diabetes and see painful insulin injections become a thing of the past.

University of Texas Health Science Center doctors used a virus as a carrier to introduce insulin-producing genes into the pancreas of rodent subjects.

Professor Ralph DeFronzo said researchers altered cells so they secreted insulin, but only in response to glucose mimicking the behavior of the bodys beta cells.

This study bypasses the autoimmune system by altering other pancreatic cells so they can co-exist with immune defenses unlike beta cells, which are rejected in Type 1 patients.

At the moment, Type 1 diabetes is treated by monitoring glucose levels and injecting artificial insulin several times a day. While technology has made management of the condition easier, a cure has been elusive until now.

The patents co-inventor, Professor Bruno Doiron, said the results had never been seen before.

It worked perfectly, Doiron said. We cured mice for one year without any side effects.

Doiron predicted the same low-risk response in humans.

If a Type 1 diabetic has been living with these cells for 30, 40 or 50 years, and all were getting them to do is secrete insulin, we expect there to be no adverse immune response.

DeFronzo said the same method of treatment has been approved almost 50 times by the US Food and Drug Administration to treat various conditions, including rare childhood diseases.

While its early days, the potential applications are promising and the researchers will now conduct a study on larger animals before any move to human trials.

Type 2 diabetes is the fastest-growing chronic condition in Australia, increasing at a faster rate than both heart disease and cancer.

The researchers discovery could have a massive impact on the lives of the 29 million Americans living with diabetes. About 86 million more are living with prediabetes, according to the CDC.

The biggest side effect of diabetes is hypoglycemia, when the level of glucose in the bloodstream is at abnormally low levels.

It can have severe side effects including seizures, inability to eat or drink, and unconsciousness, and is potentially fatal.

The new therapy precisely regulated the blood sugar of the mice a major improvement over traditional insulin therapy.

Go here to read the rest:
Researcher may have found a cure for diabetes - New York Post

Read More...

Teen makes diabetes impact abroad – Gainesville Sun

July 5th, 2017 8:43 pm

A rising Gainesville High School junior will volunteer at a Dominican Republic camp for children with Type 1 diabetes.

Cassidy ONeill has spent most of her life with Type 1 diabetes. Diagnosed at 16 months, the rising Gainesville High School junior is about to take her first trip out of the country to help other children with the disease.

ONeill, 16, will travel to Santo Domingo, the capital of Dominican Republic, to help run Campo Amigo Dominicano, a camp designed for children with Type 1 diabetes to learn how to follow a healthy lifestyle.

Type 1 diabetes occurs when ones pancreas produces too little insulin and the immune system attacks the pancreas insulin-producing cells.

As a kid, its scary, ONeill said. Shes used an insulin pump most of her life, and every 5 minutes her glucose monitor tests her blood sugar. She and her parents can check the results on their phones.

Some people arent as fortunate as Ive been, ONeill said.

In the Dominican Republic, people need blood test strips, syringes and insulin, she said. Accessible education is lacking, too.

Its really hard to find resources and support, she said.

The goal of the camp, which begins Saturday, is to educate children and empower them to live full lives in spite of their illness. Camp volunteers are asked to raise funds, and ONeill has already met the $6,500 target, selling wristbands to her fellow students and exploring other resources.

Because the camp is in the capital, children from across the country come. Its four days long, but ONeill will head out early to help plan and organize the camp. It will be her first time out of the country, although shes advocated for Type 1 diabetes awareness across the United States.

Its a big part of my life, she said.

Originally posted here:
Teen makes diabetes impact abroad - Gainesville Sun

Read More...

Study: Anti-inflammatory medication could help treat type 2 diabetes – fox5sandiego.com

July 5th, 2017 8:43 pm

SAN DIEGO An anti-inflammatory medication used for a variety of conditions could also be effective in treating type 2 diabetes, scientists with UC San Diego and the University of Michigan reported Wednesday.

In a study published in the journal Cell Metabolism, the researchers said they found a molecular signature in patients who responded to the drug amlexanox, which is used to treat asthma patients in Japan and other afflictions.

In a study of 42 obese patients with type 2 diabetes, half were given the drug for three months and the other half a placebo. Some, but not all, of the group given amlexanox responded, said Alan Saltiel, director of the UC San Diego Institute for Diabetes and Metabolic Health.

We didnt understand why, so we did a molecular analysis from biopsies of fat cells we took from patients at the beginning and end of the study, Saltiel said.

In the responder group, the level of inflammation in fat was higher than in the non-responder group at the beginning of the study, indicating that there is something about inflammation that predisposes a person to respond, he said. And, what was really amazing was that there were more than 1,100 gene changes that occurred exclusively in the responders.

According to UCSD, blood sugar, insulin sensitivity, weight and liver fat were measured. A biopsy of fat cells from each patients midsection was taken before and after the trial to measure changes in gene expression.

The researchers said amlexanox inhibits a pair of enzymes that are activated in obese mice, causing a drop in energy expenditure or reduction in calories burned. Giving obese mice the drug caused them to lose weight, while their sensitivity to insulin increased, improving their diabetes and fatty liver disease.

The human trial revealed that gene changes that occurred in the mouse model also happened in the human responder group. Blood sugar in the clinical trial patients went down as genes involved in the expenditure of energy changed, the scientists said.

Saltiel said amlexanox was promising as a type 2 diabetes treatment, but numerous questions still needed to be resolved regarding the proper dosage, frequency and other issues.

He said he plans to dive deeper into the gene changes to better understand which are most important, which affect liver fat, which translate into changes in blood sugar levels and more. He is planning a new human clinical trial with colleagues at Michigan.

The Salk Institute for Biological Studies in La Jolla assisted with the study, which was funded, in part, by the National Institutes of Health.

Go here to see the original:
Study: Anti-inflammatory medication could help treat type 2 diabetes - fox5sandiego.com

Read More...

GR8 Inspirations: Local man helps people manage their diabetes, change their lives – WFLA

July 5th, 2017 8:43 pm

TAMPA, Fla. (WFLA) Charles Mattocks found a way to take his message around the globe by creating an onlinedocu-series about his own struggles with diabetes called Reversed.

The series is about educating participants who are struggling with diabetes about how to better manage the disease.

Its taken me literally around the world. From India to the islands. I wanted to take my journey and see what it would be like if someone was just diagnosed with diabetes, said Mattocks.

Mattocks was getting national exposure as a celebrity chef when he was hit with the news that he had type 2 diabetes.

I used to think drinking ginger ale was good for you because it has ginger in it. I dont know what I was thinking. I was one of these guys, with all this chest and all of this stomach so thats when I knew I had to look in the mirror.

Looking into a mirror and through a camera lens, Mattocks quickly realized his journey was about connecting one-on-one with others.

That became a bigger journey as I saw people suffering, and I started to see people who were hurting. This is a killer, theres somebody in the hospital right now dying from a diabetes complication. Its the number one leading cause of amputation, its the number one leading cause of blindness. 80 percent of diabetes patients die from heart disease, so this is nothing to play with, said Mattocks.

The award-winning producer and bestselling author will host Reversed and will play a role in helping people hes met along his journey to change their diet, exercise and mindset about the disease. The series will feature experts such as diabetes educators, endocrinologist, therapists, nutritionist, and trainers.

There will also be surprise visits from celebrity guests who are also living with diabetes, to help encourage the contestants.

Its his mission to save those struggling with diabetes makes Charles Mattocks a Gr8 Inspiration.

STORIES OTHERS ARE CLICKING ON:

BACK TO TOP STORIES

Originally posted here:
GR8 Inspirations: Local man helps people manage their diabetes, change their lives - WFLA

Read More...

Personalized Medicine Summit Personalized Medicine …

July 5th, 2017 8:43 pm

Register Now for the Personalized Medicine Summit 2017

Sunday June 11th-Tuesday June 13th, 2017-The Summit will be held at the Life Sciences Institute, University of British Columbia, Vancouver, BC

The Personalized Medicine Initiative and partners are pleased to announce the 2nd Personalized Medicine Summit 2017, scheduled for June 11-13, 2017 at the University of British Columbia (UBC). This meeting follows on from the highly successful 1st Personalized Summit 2015 at UBC, which resulted in a consensus advisory document, the Roadmap for Bringing Personalized Medicine to British Columbians. The Summit will produce an updated Roadmap to assist government, the public and healthcare providers to implement personalized precision medicine to result in more efficient and effective healthcare.

The 2nd Summit will attract an internationally renowned faculty and will be of interest to clinicians, patient advocates, health care providers, academics and representatives from government and industry who are interested in the revolution in healthcare that is being enabled by personalized, molecularly-based medicine. We anticipate approximately 450 attendees.

The deliverable of the summit meeting will be an updated edition of our 2015 publication Roadmap for Bringing Personalized Medicine to British Columbians (see attached). This publication summarized the consensus arising from the Personalized Medicine Summit 2015 and made four major recommendations:

Contact:

the.summit@ubc.ca

Follow this link:
Personalized Medicine Summit Personalized Medicine ...

Read More...

We Just Got Two Steps Closer to Personalized Cancer Vaccines … – Mental Floss

July 5th, 2017 8:43 pm

Study by study, researchers are pushing ever closer toward identifying the gene variants to blame for inflammatory bowel disease (IBD). The latest and most promising findings were published in the journal Nature.

There are two forms of IBD: ulcerative colitis, which affects only the colon and is more common in women; and Crohn's disease, which can affect any part of the gastrointestinal tract and is slightly more common in men. Today, IBD affects between 1 and 1.3 million Americans, yet we understand very little about why it happens or why some groups of people are more susceptible than others.

It's possible and even likely, scientists say, that the root of the illness could lie in our genes. Previous studies have linked IBD to hundreds of different genetic variants, but that's as specific as they could get.

To take a closer look, researchers at three institutions collaborated to build a massive, high-resolution genetic map. They collected the genomes of 67,852 different people18,967 with Crohn's disease, 14,628 with ulcerative colitis, and 34,257 healthy people for a control groupand combed through, looking for variants unique to the folks with IBD.

Like previous researchers, they found plenty. But the new map was so detailed that its creators could zoom in further and further down, checking how likely it was that any given variant could actually cause the disease. From hundreds, they narrowed it down to just 18 variants, and had at least 95 percent certainty that these were the ones responsible. Some of these gene variants were related to processing amino acids; some seemed to interfere with healthy molecule binding; and some were tied to the switching on and off of immune or gut cells.

"We need to be careful in deciding when we are sure we have the right variant," first author Hailiang Huang, of Massachusetts General Hospital and the Broad Institute, said in a statement. "This new technique helps us to pinpoint which genetic variants are implicated in IBD with greater confidence."

The authors say that isolating IBD-related gene variants will help develop new drugs, and could someday even aid in personalized medicine by helping doctors identify which existing drugs will be most effective for their patients.

See the article here:
We Just Got Two Steps Closer to Personalized Cancer Vaccines ... - Mental Floss

Read More...

DNA testing – on the road to regenerative medicine – VatorNews

July 5th, 2017 8:42 pm

We recently had Dr. Craig Venter speak at our Splash Health 2017 event. Dr. Venter is the first person to sequence a human genome, simply put: the instructions and information about human development, physiology, and evolution. In his interview, he points out that 15 years ago, sequencing a human genome would have cost $100 million and take over nine months.

Oh how far weve come. Today, there are a number of companies helping us to analyze our genes, or basically our DNA, which make up genes, to understand our physiology. Advances in sequencing the human genome have been the foundation for this knowledge, and is ultimately paving the path toward personalized medicine - therapies that are personalized to a persons genetic code, and its cousin regenerative medicine - therapies that replace or enable damaged cells, organs to regenerate.

One company, Orig3n, is doing both. Boston-based Orig3n started out in 2014 collecting blood samples to conduct regenerative medicine studies, but later added in the ability to conduct DNA testing to learn more about a persons intelligence, or predisposition to learning languages, to knowing what vitamins theyre deficient in.

Its an interesting an unique funnel the company has created for itself on its way to solve big problems with regenerative medicine, which seems more in its infancy than DNA testing.

To that end, Orig3ns DNA testing business has taken off.

In order to be tested, you take a cotton swab and swab the inside of your cheek to collect DNA samples from the cells inside your mouth. Alternatively, one could spit in a tube, which is how 23andMe collects samples of DNA.

From there, Orig3n breaks down the cells to open up the DNA, which is inside the nucleus of the cell. The DNA is then purified and put into a genetic test panel. Your DNA is then analyzed against other DNA that have been collected and studied.

The analysis of the DNA is pretty standard. What differentiates its products, according to Robin Smith, Founder and CEO, is how the analysis is packaged and how quickly the results are turned around. The whole genome sequencing world has been around for 15 years and is fairly commoditized, said Smith. The same thing is happening with DNA detection. The biggest differentiator for Orig3n is that it delivers the data in ways that are understandable, said Smith.

For instance, on Orig3n, tests focus on an analysis of your skin to perfect your skincare routine, or about your strength and intelligence. Tests range from $20 to $100.

On Everlywell, you can take a DNA test to measure your sensitivity to foods. Or for around $239, it appears you can test to see if you have HIV, Herpes Type 2 and other sexual diseases.

On 23andMe, you can pay $199 to learn what proportion of your genes come from 31 populations worldwide, or what your genetic weight predisposes you to weigh vs an average and what are some healthy habits of people with your genetic makeup [though personally these habits seem to be good for anyone regardless of genetic makeup].

But for Orig3n, the DNA tests are just a good business while also a funnel to the bigger problem theyre trying to solve, and for which they recently raised $20 million for: Regenerative medicine.

Before offering the DNA tests, Orig3n was taking and continues to take blood samples, reprogramming cells to go back to a state three days prior. And from there, they can grow certain tissues. The purpose of Orig3n is to create cell therapies for various diseases and disorders.

In the next fives year, there will be real live therapies to repairing the degeneration of your eyes or performing some cardiac repair, Smith predicted. It feels like 1993 when I used a phone line to dial into the Internet, then seven years later we had the boom. We think regenerative medicine - getting your body to induce itself to rejuvenate parts that are broken - is where the Internet was in 1993.

Read more from the original source:
DNA testing - on the road to regenerative medicine - VatorNews

Read More...

After 50 Years, Equine Vet Not Ready for the Pasture – Southern Pines Pilot

July 5th, 2017 8:42 pm

Fresh from a teaching stint at Cornell Universitys veterinary school, moving to Southern Pines in 1971 made Fred McCashin feel a bit like a pioneer on the frontier of equine medicine.

Considering the manicured pastures of todays Southern Pines horse country and the miles of weathered post-and-rail fence lines in Moore Countys equestrian enclaves, that feeling is difficult to imagine.

But back then, much of the equestrian community here was seasonal fox hunters and harness racers and N.C. States College of Veterinary Medicine wouldnt be up and running for more than a decade.

McCashin, 76, recently attended the 50th reunion of his vet school class at the University of Pennsylvania. His Youngs Road practice, Carolina Equine Clinic, is celebrating its 40th year in business this month.

He came to North Carolina not to be a solo practitioner, but to direct the N.C. Veterinary Research Foundation. Established as a nonprofit by a group of veterinarians hoping to lay the foundation for a veterinary school, the facility is now the N.C. State Equine Research center on U.S. 1 north of Southern Pines.

Dr. Fred B. McCashin, shown here with Attaboy Roy, establshed the Carolina Equine Clinic in 1977. (Photo by Ted Fitzgerald/The Pilot)

Other opportunities were available: continuing to teach at Michigan State, or working as the staff veterinarian for the racing stable of a prominent French art dealer. At that point, though, hed had enough of difficult characters and the politics embroiled in academia. And the chance to fill a void for the states thriving horse business by performing surgery on a referral basis held its own fascination.

That was really sorely needed because there were very few veterinarians that would even attempt to do surgery in the state of North Carolina, said McCashin, who recalled his six years at the research foundation as nonstop work.

I could stay up all night operating on a case and you didnt have any time off the next day. It was like working on the prairies. It was a nice building and all, we had the facilities, but I was trying to get veterinarians in the field to come in with their cases and give me a hand, because sometimes you just cant do it all by yourself.

He opened Carolina Equine Clinic in 1977, working out of the barn on the property, then adding a clinic and lab building.

This is just a little modest thing, and I never made it any bigger, he said. I thought about having branches in Wilmington and other places where no one was doing surgeries, but I was busy enough here that I couldnt get away.

The clinic is strewn with relics from McCashins career in the form of calcified masses extracted from patients. One, the size of two fists, he found in 1982 while performing emergency colic surgery on a Morgan horse from a Raleigh farm before N.C. State started surgery.

In that particular case, McCashin rushed to the clinic on Halloween his children missed trick-or-treating that year not a moment too soon as he opened the patients abdomen to find it full of manure. Though that could have been a death sentence, the horse made a full recovery.

The owner was here and I said this is bad but I just took it and heaved it over the side and everything else looked reasonably clean, he recalled. The stone was there and it had ruptured his small colon. So we cleaned it up, took out the busted section and stuck it back together again and I said well just see how its going to go.

I dont ask the kids if they remember that, he said ruefully.

Its that kind of episode that remains so vivid to the longtime veterinarian that it might as well have happened yesterday. So too with the tough cases, solved through months of rehabilitation and sheer force of will like Jet Murmur, a Thoroughbred colt who broke his leg at around six months of age.

(Photo by Ted Fitzgerald/The Pilot)

In six months I think I had him on the table maybe seven times because the plates kept getting a little bit loose and Id go back in and tighten up the screws and put new screws in and kept altering the thing, McCashin said.

I remember taking him on a longe THIS IS CQ line up there on the hill and taking him through the woods and trotting him over logs and stuff. He was a long yearling by the time I sent him home and he ended up being a productive stallion.

McCashin developed a specific interest in orthopedic surgery as a student protg of Jacques Jenny, who invented the technique of bone plating inspired by Swiss compression equipment used to treat skiing-related fractures in humans. He remembers plating the first broken leg at Ohio State University while studying as a postdoctoral student there.

It was a fancy Quarter Horse filly by a stallion called Gunsmoke, he recalled. Its always fun if you happen to save the life of a horse thats in a line of really well-bred animals.

Appreciation of a good horse was in McCashins blood long before he became a veterinarian. His father, Arthur, was captain of the U.S. national show jumping team that won bronze at the 1952 Helsinki Olympics.

Growing up on a derelict polo field in New Jersey, McCashin and his older brother jockeyed their fathers steeplechase horses and jumpers. But it was on his fathers advice that he decided to forego a chance to ride in the Olympics himself.

Dad told me, If you had a horse and went to the Tokyo games in 64 and you win a gold medal, you put the gold medal and a dime on the counter and youll get a cup of coffee, McCashin said.

I did ride with the team for quite a while, just never competed, but I exercised some fancy, fancy jumpers. I was lucky to be on Ksar dEsprit and Fire One and San Lucas and horses that are in the history books.

Though he never got to ride in the Olympics, McCashin had a backstage pass to the 1976 games in Montreal as the official vet for the United States Equestrian Team and to the 1996 Atlanta Olympics as an officiating vet for the international governing body for equestrian sports known as the FEI matching the competition horses to their international passports and drug testing a random sample.

While he stepped back from work as a competition vet last year, retiring completely isnt in McCashins plans. Not that he hasnt considered it. But after 50 years, he isnt sure he knows how not to be a horse doctor.

For the last few years, the clinic has hired younger veterinarians to do the bulk of the everyday work driving around Moore and nearby counties vaccinating horses, performing dental work, and other preventive maintenance. McCashins current associate, Beth Susen, has a knack for tricky reproductive cases.

Several of the areas equine veterinarians initially built their reputations in Southern Pines while working as McCashins associate vets. Perhaps as notably, Dean Richardson at UPenns New Bolton Center, who rose to stardom in the horse world when he operated on 2006 Kentucky Derby winner Barbaro after he broke several bones in his right hind leg at the start of the Preakness Stakes, worked at Carolina Equine Clinic before he was even admitted to vet school.

I saw him when I went up for the 50th reunion and reminded him he used to plant trees for us down here, McCashin joked.

McCashin still performs some surgeries in the clinics padded operating room, but like most vets refers severe colic cases and broken limbs to N.C. State. In 40 years of veterinary practice, there has been plenty of development to keep abreast of things that dont involve picking up a scalpel.

IRAP, stem cell therapy and other regenerative therapies have replaced counter-irritating methods in treating common tendon and soft tissue injuries in horses. The telltale scars of pinfiring applying extreme heat or cold to a horses leg were once frequent markings in horses retiring from the racetrack but are now out of vogue among most trainers.

(Photo by Ted Fitzgerald/The Pilot)

You would do counterirritation just to give the horse time off, McCashin recalled.

The advent of digital imaging has made diagnosing lameness easier than ever but McCashin failed to join N.C. States faculty in their enthusiasm when the school first acquired an equine MRI system.

Its a great research tool and you can definitely learn a whole lot more by getting that kind of detail, but they get really reliant on some of that technology when they get out of school, so theyre stuck, he said. I always tell them you can use your ears and your eyes and your fingers, if you learn to use them, to discover a lot on a horse.

McCashins patients range from carbon copies of the horses he rode in his showjumping heyday to horses of a different color entirely: Standardbreds training in Pinehurst, barrel racing Quarter Horses in Carthage, and mammoth jack donkeys in Wagram.

Riding a Paso Fino in the Andes on a recent vacation to Peru, it was all he could do not to conduct an impromptu study of the hardy horses respiration rates at varying elevation levels.

When you really love doing the kind of work you do, its hard to retire, he said. Its hard to give that up. You like to be selective in what you do and what you dont do. Ive had surgeries to repair this and repair that, my back, and then I had my heart ablated for a-fib, so I just try not to get sedentary.

Follow this link:
After 50 Years, Equine Vet Not Ready for the Pasture - Southern Pines Pilot

Read More...

State looks to WSU for elk hoof disease research – goskagit.com

July 5th, 2017 8:42 pm

The state Department of Fish & Wildlife continues to investigate the cause and spread of a hoof disease affecting elk in the state, including in Skagit County.

The disease is caused by a bacteria that can cause hoof deformities. The bacteria is known to also cause lameness in affected livestock.

Its spread into northwest Washington remains a mystery, as the disease was first found in southwest parts of the state years earlier.

Story continues below video

In late 2015, an elk with the disease was found on Highway 20 in Skagit County. In 2016, two elk north of the Whatcom-Skagit county line were also found to have the disease.

A new state law directs Fish & Wildlife and Washington State University to continue researching how the disease spreads between animals and from one location to another.

The law was sponsored by Sen. Kirk Pearson, R-Monroe, who chairs the Senate Natural Resources and Parks Committee.

The law takes effect July 21. The recently passed state budget includes about $1.5 million toward the laws goals.

The law directs the WSU College of Veterinary Medicine to monitor elk herds, identify causes for the spread of the disease and come up with solutions to prevent it.

Pearson said in a news release that action is needed because livestock farmers have expressed fear of the disease affecting their herds.

WSUs College of Veterinary Medicine has long been a partner in the states work on the issue, including having six representatives on Fish & Wildlifes Technical Advisory Group for the elk hoof disease, said Fish & Wildlife statewide elk specialist Brock Hoenes.

WSU College of Veterinary Medicine spokesman Charlie Powell said the universitys Washington Animal Disease Diagnostic Laboratory received several elk hooves from Fish & Wildlife leading up to the diagnosis of the hoof disease.

We dont need to see any more hooves ... We have moved into the next step of needing to do comprehensive research, he said.

With the law set to take effect and funding secured, the university will likely designate a faculty member to oversee elk hoof disease research and to dedicate some staff to handle experiments, Powell said.

Fish & Wildlife veterinarian Kristin Mansfield said beyond knowing that the disease is at least in part caused by an infectious bacteria, many questions remain.

Questions that need answers include whether the bacteria can persist in the environment, how the disease is passed from one elk to another, how the disease affects elk survival and population sizes, where in the state the disease is being seen and whether some elk have a genetic resistance to it.

WSU is one of several universities and government labs Fish & Wildlife has collaborated with on research about the disease.

Mansfield said WSUs work helped diagnose the disease.

They had a key role in the early years starting in about 2009, when the disease first emerged in the landscape in elk in southwest Washington, she said. We collected several samples from elk in those early years and the majority of those samples went to WSU, so they played a key role in helping us diagnose what the disease was.

Masnsfield said along with work at U.S. Department of Agriculture labs, the University of Liverpool and other locations, WSU can continue helping to reveal more information about the hoof disease.

Meanwhile, Fish & Wildlife continues to seek public reports of hoof deformities in elk killed in collisions, killed by hunters or observed limping.

Hoenes said reports have helped Fish & Wildlife confirm the disease in Skagit, Whatcom, Thurston and Mason counties in recent years.

Skagit County residents have reported seeing one or more limping elk in September and December 2015, March and August 2016, and March 2017.

Those are a handful of the 1,100 reports Fish & Wildlife has received statewide since it started taking online reports in 2012.

I really feel for people who are seeing this out there in the wild, said Powell, who has also received calls from distressed members of the public who have seen elk with deformed hooves.

See the article here:
State looks to WSU for elk hoof disease research - goskagit.com

Read More...

Kidney disease: how could stem cells help? | Eurostemcell

July 5th, 2017 8:41 pm

The kidneys are towards the back of the body, roughly 10 cm above the hipbones and just below the ribcage. They are the bodys filtering units, maintaining a safe balance of fluid, minerals, salts and other substances in the blood. They produce urine to remove waste and harmful substances from the body. They also produce several hormones: erythropoietin (EPO), which acts on the bone marrow to increase the production of red blood cells; calcitriol (active Vitamin D3), which promotes absorption and use of calcium and phosphate for healthy bones and teeth; and the enzyme renin, which is involved in monitoring and controlling blood pressure.

The key working component of the kidney is the nephron.

The nephron - the functional unit of the kidney:The best evidence so far for stem cells in the adult kidney suggests they might be found in the blue area, called the urinary pole.

The nephron is made up of:

Microscope image of kidney tissue showing tubules. One tubule is highlighted to show epithelial cells (blue), cell nuclei (green) and the tubule lumen (dark center).

See the article here:
Kidney disease: how could stem cells help? | Eurostemcell

Read More...

UW-Madison scientists, inspired by old bones, find new strategy for … – Madison.com

July 5th, 2017 8:41 pm

Protein-based drugs are increasingly used to treat bone disorders, kidney disease, wounds, arthritis and cancer. But the proteins frequently degrade, limiting their therapeutic potential and sometimes causing immune reactions.

UW-Madison scientists, inspired by proteins found intact in centuries-old human bones, created a mineral coating that mimics bone and appears to keep proteins stable.

Whats needed is a delivery system that remains localized, releases the protein over an extended time frame and keeps the protein active, said William Murphy, a UW-Madison professor of biomedical engineering.

Murphy and his colleagues, including Xiaohua Yu of the UW School of Medicine and Public Health, reported on their mineral coating constructed at the miniature level of biology known as the nanoscale in this weeks edition of the journal Advanced Materials.

In a lab dish, the mineral coating released a protein, called basic fibroblast growth factor, which remained active for more than a month. When the protein was released by a commonly used system made with polymers, or plastics and rubber, it stayed active for less than a week.

In rabbits, the scientists repaired Achilles tendon tears by stitching together the severed portions of the tendon. Sutures lined with mineral coating that released two growth factors healed the injury better than regular sutures, Murphy said.

Even after the mineral coatings were subject to harmful solvents in the lab dish and sterilization of the sutures conditions that can cause proteins to degenerate the proteins remained intact.

We really can hit these proteins with a sledgehammer, so to speak, and they remain protected by the mineral coating, Murphy said.

Murphy and his colleagues knew about archaeological discoveries of growth factors and other proteins preserved in human teeth and bones from the Middle Ages. But it was a 2010 report about DNA extracted from a 19,000-year-old emu eggshell in Australia that really gave him the idea for medical applications.

It triggered a greater interest in how powerful these calcified tissues can be for stabilizing biologic molecules, said Murphy, co-director of UW-Madisons Stem Cell and Regenerative Medicine Center. If we could recreate some critical aspects of mineralized tissues, they may serve as a template for protein stabilization.

He and his team created the coating by soaking a special surface in a solution containing mineral ions found in human blood, and growing crystals. Its not all that different from a really simple crystal growth kit that a grammar school student might buy, he said.

The scientists are now using the mineral coating in rodent studies of protein therapies for rheumatoid arthritis.

Other applications could include knee and hip implants and drugs for cancer, wounds and bone disorders. The system might also help improve drugs such as erythropoietin, or EPO, used to boost red blood cells damaged by kidney disease. The drugs unstable proteins can cause immune system reactions.

If proteins could be better stabilized in drug delivery, patients might need injections only once every month or two instead of every day or week, Murphy said.

Originally posted here:
UW-Madison scientists, inspired by old bones, find new strategy for ... - Madison.com

Read More...

Benefit to assist former Litchfield paramedic – Crow River Media

July 5th, 2017 8:41 pm

Knowing hes helped many people in times of medical crises, friends and family of Jesse Wadsworth want to lift up the former Litchfield EMT/paramedic in his own time of need.

Wadsworth was diagnosed with multiple myeloma, a rare bone marrow cancer, in mid-May. A former Willmar resident who recently moved to Clara City, he has worked as an EMT/paramedic in Meeker and Stearns counties for 18 years, including 13 years in Litchfield.

Wadsworth started as an EMT in Litchfield in 2003. He became a paramedic in 2008 and served as a captain for Gold Cross Ambulance in Litchfield from 2012 to 2016.

Wadsworth and his family wife, Carrie, and sons, Ben, 19, Blake, 15, and Matthew, 11 have made the Willmar area their home for the past 18 years.

Family and friends have organized a benefit dinner and silent auction, set for July 28, at the Spicer American Legion (155 Lake Ave. N.) A suggested donation of $10 will be accepted for the meal, and drinks will be available.

After his cancer diagnosis May 17, Wadsworth immediately began intraveneous and oral chemotherapy, according to his sister, Misty Maher, who is helping organize the benefit. On May 23, he was admitted to Mayo Clinic in Rochester for two weeks due to kidney failure. Along with chemotherapy, he began plasmapharisis (similar to dialysis) and blood transfusions due to anemia.

Wadsworth continues to travel weekly to Mayo Clinic for chemotherapy treatments. In a few months, after he concludes chemotherapy treatment, he will begin to receive stem cell transplants. He will be confined to a clean room at the Mayo hospital for weeks at a time, Maher said.

Wadsworth is the familys primary financial provider, but due to the serious nature of his condition and the medical treatment it necessitates, he is unable to work at this time, Maher said.

Wadsworths wife is his primary caregiver and travels with him to each appointment, staying until his release.

Maher said funds raised at the benefit will assist with medical expenses, but, just as important, she hopes his friends, family, present and past colleagues and the communities hes served will gather around him and lift him up with support, giving and prayer to help ease a burden and feel surrounded by love during this difficult time.

Maher said donations for the benefit groceries for dinner, dcor, silent auction items and cash or gift certificates are appreciated. To volunteer or to donate, contact Maher at 320-262-1498 or Wadsworths sister-in-law, Nickie Johnson, at 304-790-4668.

Read the original post:
Benefit to assist former Litchfield paramedic - Crow River Media

Read More...

Omeros: Next Big Thing In Biotech – Seeking Alpha

July 5th, 2017 8:41 pm

Omeros Corporation (OMER) is a biopharmaceutical company which develops and commercialize both small-molecule and protein therapeutics for the treatment of inflammation, coagulopathies and disorders of the central nervous system. Omeros has one of the most diverse pipelines and recently emerged as a strong investment target. The company has one marketed product and four drug candidates in clinical stage with various others in preclinical stage in their pipeline. A company with 12 drug candidate under development in their clinical and pre clinical pipeline has lot of potential and could turn out to be a company with blockbuster portent in the next couple of years.

Omeros first marketed product Omidria, a 1% phenylephrine and 0.3% ketorolac injection is a part of its proprietary PharmacoSurgery platform. It is primarily designed to prevent the intraoperative miosis (pupil constriction) during cataract surgery or intraocular lens (IOL) replacement and to reduce postoperative ocular pain. The main benefit from Omidria is that it prevents damage to the ocular structures, especially the iris, during surgery as a result of smaller pupil size.

Omidria is a pupil dilator that helps eye surgeons operate on lenses with fewer complications. In 2016, Omidria generated over $41 million in total sales, and in Q1 2017, it generated $12.3 million in sales. At present, nearly 3 million cataract surgeries are performed each year in the U.S. alone and assuming that it works better than any other traditional method of maintaining pupil dilation during surgery, this drug has billion dollar potential.

The pipeline for Omeros is diverse and quite extensive. OMS721 is the lead product candidate most likely to hit the market next. Currently, OMS721 is being tested in three areas; atypical hemolytic uremic syndrome (aHUS, which is a rare life threatening disorder resulting in blood clot throughout the body), hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA, a disorder triggered by stem cell transplant surgery), and immunoglobulin A nephropathy (IGAN, a disease where IgA antibodies build up in the kidneys leading to inflammation and possible kidney failure). OMS721 for treating Atypical Hemolytic Uremic Syndrome is already in the Phase 3 stage.

OMS721 is a human monoclonal antibody targeting a protein called "MASP-2.", which when inhibited can help prevent damaging immune reactions seen in the above disorders. OMS721 recently received the breakthrough therapy designation from the FDA for treating IgA Nephropathy and other renal diseases. FDAs breakthrough therapy designation enables expedited development and review of a drug candidate for the treatment of a serious or life-threatening disease. Proteinuria (uACR) is an important marker for disease progression in patients with IgA nephropathy, and improvement in proteinuria is associated with improved clinical outcomes. The company announced positive data from its Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, including IgA nephropathy. As reported for the three patients who completed treatment, mean improvement in uACR values was 76% and mean decrease in 24-hour urine protein levels was 66%. Concurrently, daily steroid doses for all patients were substantially reduced or completely eliminated.

Omeros also is pursuing accelerated approval for OMS721 in aHUS. The FDA has already granted fast track designation for OMS721 in patients with aHUS and orphan designation for OMS721 in patients with complement-mediated TMAs, including aHUS and HSCT-TMA. The potential of the lead pipeline candidate OMS721 of Omeros seems to be even more exciting than Omidrias. Its lead clinical-stage candidate OMS721 has shown positive data from Phase 2 clinical trials in both renal disorders and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). If the results achieved in small and mid-stage clinical trials can be repeated in late-stage studies, which are currently underway, Omeros could have a second drug with $1 billion per year sales potential.

A success from the company's first drug, and encouraging clinical trial results from the lead product candidate OMS721 which is in late-stage development, has produced strong movements in the company stock in the recent past. It gained close to 150 percent this year. The company has multiple drugs in its pipeline, which means that the company needs to have a steady cash flow to ensure that the development work is carried out without any hindrance.

The company has several upcoming catalysts as it progresses with the clinical trial of its lead drug candidates . The companys lead product candidate OMS721 is in Phase 3. Any positive news on this candidate will help propel the stock further. Omeros Corporation's market cap has more than doubled this year to about $1 billion but there is plenty of potential still left. If Omidria and OMS721 continue on their success to blockbuster status, the stock could give huge incentives over the next couple of years.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Excerpt from:
Omeros: Next Big Thing In Biotech - Seeking Alpha

Read More...

Smelling your food makes you fat | Berkeley News – UC Berkeley

July 5th, 2017 8:40 pm

iStock photo

Our sense of smell is key to the enjoyment of food, so it may be no surprise that in experiments at the University of California, Berkeley, obese mice who lost their sense of smell also lost weight.

Whats weird, however, is that these slimmed-down but smell-deficient mice ate the same amount of fatty food as mice that retained their sense of smell and ballooned to twice their normal weight.

In addition, mice with a boosted sense of smell super-smellers got even fatter on a high-fat diet than did mice with normal smell.

The findings suggest that the odor of what we eat may play an important role in how the body deals with calories. If you cant smell your food, you may burn it rather than store it.

These results point to a key connection between the olfactory or smell system and regions of the brain that regulate metabolism, in particular the hypothalamus, though the neural circuits are still unknown.

This paper is one of the first studies that really shows if we manipulate olfactory inputs we can actually alter how the brain perceives energy balance, and how the brain regulates energy balance, said Cline Riera, a former UC Berkeley postdoctoral fellow now at Cedars-Sinai Medical Center in Los Angeles.

Humans who lose their sense of smell because of age, injury or diseases such as Parkinsons often become anorexic, but the cause has been unclear because loss of pleasure in eating also leads to depression, which itself can cause loss of appetite.

The new study, published this week in the journal Cell Metabolism, implies that the loss of smell itself plays a role, and suggests possible interventions for those who have lost their smell as well as those having trouble losing weight.

Sensory systems play a role in metabolism. Weight gain isnt purely a measure of the calories taken in; its also related to how those calories are perceived, said senior author Andrew Dillin, the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research, professor of molecular and cell biology and Howard Hughes Medical Institute Investigator. If we can validate this in humans, perhaps we can actually make a drug that doesnt interfere with smell but still blocks that metabolic circuitry. That would be amazing.

Riera noted that mice as well as humans are more sensitive to smells when they are hungry than after theyve eaten, so perhaps the lack of smell tricks the body into thinking it has already eaten. While searching for food, the body stores calories in case its unsuccessful. Once food is secured, the body feels free to burn it.

After UC Berkeley researchers temporarily eliminated the sense of smell in the mouse on the bottom, it remained a normal weight while eating a high-fat diet. The mouse on the top, which retained its sense of smell, ballooned in weighton the same high-fat diet.

The smell-deficient mice rapidly burned calories by up-regulating their sympathetic nervous system, which is known to increase fat burning. The mice turned their beige fat cells the subcutaneous fat storage cells that accumulate around our thighs and midriffs into brown fat cells, which burn fatty acids to produce heat. Some turned almost all of their beige fat into brown fat, becoming lean, mean burning machines.

In these mice, white fat cells the storage cells that cluster around our internal organs and are associated with poor health outcomes also shrank in size.

The obese mice, which had also developed glucose intolerance a condition that leads to diabetes not only lost weight on a high-fat diet, but regained normal glucose tolerance.

On the negative side, the loss of smell was accompanied by a large increase in levels of the hormone noradrenaline, which is a stress response tied to the sympathetic nervous system. In humans, such a sustained rise in this hormone could lead to a heart attack.

Though it would be a drastic step to eliminate smell in humans wanting to lose weight, Dillin noted, it might be a viable alternative for the morbidly obese contemplating stomach stapling or bariatric surgery, even with the increased noradrenaline.

For that small group of people, you could wipe out their smell for maybe six months and then let the olfactory neurons grow back, after theyve got their metabolic program rewired, Dillin said.

Dillin and Riera developed two different techniques to temporarily block the sense of smell in adult mice. In one, they genetically engineered mice to express a diphtheria receptor in their olfactory neurons, which reach from the noses odor receptors to the olfactory center in the brain. When diphtheria toxin was sprayed into their nose, the neurons died, rendering the mice smell-deficient until the stem cells regenerated them.

Separately, they also engineered a benign virus to carry the receptor into olfactory cells only via inhalation. Diphtheria toxin again knocked out their sense of smell for about three weeks.

In both cases, the smell-deficient mice ate as much of the high-fat food as did the mice that could still smell. But while the smell-deficient mice gained at most 10 percent more weight, going from 25-30 grams to 33 grams, the normal mice gained about 100 percent of their normal weight, ballooning up to 60 grams. For the former, insulin sensitivity and response to glucose both of which are disrupted in metabolic disorders like obesity remained normal.

Mice that were already obese lost weight after their smell was knocked out, slimming down to the size of normal mice while still eating a high-fat diet. These mice lost only fat weight, with no effect on muscle, organ or bone mass.

The UC Berkeley researchers then teamed up with colleagues in Germany who have a strain of mice that are supersmellers, with more acute olfactory nerves, and discovered that they gained more weight on a standard diet than did normal mice.

People with eating disorders sometimes have a hard time controlling how much food they are eating and they have a lot of cravings, Riera said. We think olfactory neurons are very important for controlling pleasure of food and if we have a way to modulate this pathway, we might be able to block cravings in these people and help them with managing their food intake.

Co-authors of the paper are Jens Brning, director of the Max Planck Institute for Metabolism Research in Cologne, Germany, and his colleagues Eva Tsaousidou, Linda Engstrm Ruud, Jens Alber, Hella Brnneke and Brigitte Hampel; Jonathan Halloran, Courtney Anderson and Andreas Stahl of UC Berkeley; Patricia Follett and Carlos Daniel de Magalhaes Filho of the Salk Institute for Biological Studies in La Jolla, California; and Oliver Hahn of the Max Planck Institute for Biology of Ageing in Cologne.

The work was supported by the Howard Hughes Medical Institute, the Glenn Center for Research on Aging and the American Diabetes Association.

RELATED INFORMATION

Originally posted here:
Smelling your food makes you fat | Berkeley News - UC Berkeley

Read More...

Page 970«..1020..969970971972..980990..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick